ConductScience.org, home

Trial · NCT00768300

Results by group28

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Time to Death or Disease (IPF) Progression.Ambrisentan84.14Inter-Quartile Range 36.00 to NAweeks
Time to Death or Disease (IPF) Progression.PlaceboNAInter-Quartile Range 60.00 to NAweeks
Proportion of Participants With No Disease Progression or Death at 48 WeeksAmbrisentan65percentage of participants
Proportion of Participants With No Disease Progression or Death at 48 WeeksPlacebo80percentage of participants
Change in FVC % Predicted at Week 48Ambrisentan-10.24Standard Deviation 25.95percent change in FVC % predicted
Change in FVC % Predicted at Week 48Placebo-5.28Standard Deviation 15.68percent change in FVC % predicted
Change in DLCO % Predicted at Week 48Ambrisentan-2.68Standard Deviation 27.60percent change in DLCO % predicted
Change in DLCO % Predicted at Week 48Placebo-11.28Standard Deviation 32.06percent change in DLCO % predicted
Change in 6MWT at Week 48Ambrisentan-52.5Standard Deviation 148.7meters
Change in 6MWT at Week 48Placebo-10.6Standard Deviation 89.8meters
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the Short-Form 36® (SF-36)AmbrisentanPhysical function-1.65Standard Deviation 10.86units on a scale
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the Short-Form 36® (SF-36)PlaceboPhysical function-2.60Standard Deviation 7.25units on a scale
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the Short-Form 36® (SF-36)AmbrisentanGeneral Health-2.81Standard Deviation 9.77units on a scale
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the Short-Form 36® (SF-36)PlaceboGeneral Health-1.95Standard Deviation 8.63units on a scale
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the Short-Form 36® (SF-36)AmbrisentanVitality-1.67Standard Deviation 12.67units on a scale
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the Short-Form 36® (SF-36)PlaceboVitality-0.12Standard Deviation 7.69units on a scale
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the St. George's Respiratory Questionnaire (SGRQ)AmbrisentanSymptoms Score3.30Standard Deviation 22.11units on a scale
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the St. George's Respiratory Questionnaire (SGRQ)PlaceboSymptoms Score2.84Standard Deviation 20.43units on a scale
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the St. George's Respiratory Questionnaire (SGRQ)AmbrisentanActivity Score5.54Standard Deviation 19.38units on a scale
Change in Quality of Life (QOL) Score at Week 48 as Assessed by the St. George's Respiratory Questionnaire (SGRQ)PlaceboActivity Score2.05Standard Deviation 16.47units on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00768300/results